摘要:
The present invention relates to nucleic acid sequences and proteins derivable therefrom that have been identified in Sorangium cellulosum, which proteins are catalytically active or participate in the biosynthetic pathway of disorazoles. The invention provides novel sequences which are necessary components of the disorazole biosynthetic pathway in addition to genes dszA-D.
摘要:
The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.
摘要:
The invention relates to disorazoles of the general formula I, which are employed as medicaments, preferably for the treatment of oncoses, in particular in the case of pharmaceutical resistance to other active compounds and in the case of metastasizing carcinoma. The possible uses are not restricted to oncoses.
摘要:
The present invention relates to a novel group of compounds having antibiotic, antifungal and/or cytostatic properties, which are obtainable from myxobacteria, especially of the genus Sorangium, preferably Sorangium cellulosum. One representative of this group of compoundsis currently named Disorazole Z and Disorazole Z-epoxide, respectively, with specific substituents and specific unsaturated bonds to its cyclic core structure:
摘要:
The invention relates to compounds of the following general formula I ##STR1## especially the compound of formula Ia referred to as thiangazole ##STR2## their pharmaceutically acceptable acid addition salts, processes for their preparation and therapeutic compositions and compositions that can be used in crop-protection.
摘要:
The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration; R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy or .beta.-glucopyranosyloxy, and to the hydrates and salts thereof, especially pharmaceutically acceptable salts.The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium celulosum and are effective antiobiotics.
摘要翻译:本发明涉及式(I)的环状抗生素,其中前缀R表示相邻碳原子上的取代基为R构型; 前缀S表示相邻碳原子上的取代基为S构型; R1是氢或羟基,R2是羟基或β-吡喃葡萄糖基氧基,以及其水合物和盐,特别是药学上可接受的盐。 式Ⅰ化合物是通过使用种类Sorangium celulosum的菌株So ce 12(NCIB 12134)进行发酵而制备的,并且是有效的抗生素。
摘要:
The invention provides a compound termed Carolacton having the structure and derivatives thereof for medical use against biofilm formation by bacteria.
摘要:
The invention provides novel Thuggacin-Type macrolide compounds which form rearrangement products forming a lacton bond to different carbon atoms. The novel compounds can be produced by fermentation of Sorangium cellulosum and Chondromyces crocatus and can be isolated by adsorption and chromoatograhic processing steps. The compounds are found to have antibiotic activity. The invention also relates to Thuggacin A, Thuggacin B, Thuggacin C, 13-Methyl-Thuggacin A, Thuggacin CMC-A, Thuggacin CMC-B and Thuggacin CMC-C AS Antimycobacterial Agents.
摘要:
The invention provides novel Thuggacin-Type macrolide compounds which form rearrangement products forming a lacton bond to different carbon atoms. The novel compounds can be produced by fermentation of Sorangium cellulosum and Chondromyces crocatus and can be isolated by adsorption and chromoatograhic processing steps. The compounds are found to have antibiotic activity. The invention also relates to Thuggacin A, Thuggacin B, Thuggacin C, 13-Methyl-Thuggacin A, Thuggacin CMC-A, Thuggacin CMC-B and Thuggacin CMC-C AS Antimycobacterial Agents.
摘要:
The invention relates to cyclic antibiotics of formula ##STR1## wherein the prefix R represents that the substituents on the adjacent carbon atom are in the R configuration; the prefix S represents that the substituents on the adjacent carbon atom are in the S configuration;R.sub.1 is hydrogen or hydroxy and R.sub.2 is hydroxy and salts thereof, especially pharmaceutically acceptable salts.The compounds of formula I are prepared by fermentation using the strain So ce 12 (NCIB 12134) of the species Sorangium cellulosum and are effective antibiotics.